Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a ...

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on GILD: Gilead Sciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Gilead Sciences, a Bay Area-headquartered biotech and pharmaceutical company, is laying off 104 workers in Foster City, with ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy ...

Gilead Sciences, Inc.'s (NASDAQ:GILD) stock was strong despite it releasing a soft earnings report last week. However, we ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...

For the year to September 2024, Gilead Sciences had an accrual ratio of -0.24. That implies it has very good cash conversion, and that its earnings in the last year actually significantly ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...